Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Growth Metrics

Mitesco (MITI) Asset Writedowns and Impairment (2020 - 2025)

Mitesco has reported Asset Writedowns and Impairment over the past 3 years, most recently at -$17651.0 for Q4 2025.

Quarterly Asset Writedowns and Impairment changed N/A to -$17651.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8700.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $8700.0 for FY2025, N/A changed from the prior year.
Asset Writedowns and Impairment was -$17651.0 for Q4 2025 at Mitesco, down from $6976.0 in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $83810.0 in Q1 2023 and troughed at -$17651.0 in Q4 2025.